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ABSTRACT 
Background: The extended-spectrum β-lactamase (ESBL) carbapenems-resistant Klebsiella isolates are considered one of the most 
significant challenging in the treatment of patients in hospitals. The aim of this study was to determine the prevalence of important 
carbapenem resistance genes ESBL subtypes and between K. pneumoniae from patients at hospital in Tehran, Iran. 
Methods: Fifty-four isolates of K. pneumoniae were isolated from Shariatee Hospital in Tehran from February 2013 to July 2016. 
Antibiotic testing was done by using the standard disk diffusion method and E-test MIC. The confirmation of carbapenemase 
activity was performed using an MHT and a new method called the carbapenem inactivation method test (CIM). Finally, a 
polymerase chain reaction (PCR) and sequencing of related genes was performed.  
Results: Our PCR data demonstrate that blaCTX-M group’s 40 (81.4%) genes were the most prevalent in our hospital followed by 
group genes blaCTX-M-3 (18.51%) and blaCTX-M-2 (20.38%). The distribution of the CTX-M group revealed that blaCTX-M-15 23 (42.6%) was 
the dominant subtype. The coexistence of multiple genes included blaTEM, CTX-M and blaSHV, and CTX-M The presence of 
blaNDM1, blaOXA-48, and blaKPC were identified in the carbapenem-resistant isolates, 22 (40.7%), 10 (18.5%), and 7 (12.9%) 
respectively. 
Conclusion: Our research showed that a CIM test for the first time in Iran is possible and has a high facility for the fast 
identification of carbapenem-resistant Klebsiella (CRK). We are encountered with the emergence of CTX-M, OXA-48, KPC, and 
NDM1 harboring CRK strains in our hospitals. Therefore, the treatment of patients infected with these isolates will be an important 
future concern in our clinical settings.  
Running Head: Resistance genes among carbapenem-resistant Klebsiella pneumonia  
Keywords: New Delhi metallo-beta-lactamase-1, Klebsiella pneumoniae, Carbapenem, Extended-spectrum ß-lactamase 
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ABSTRAIT 
Contexte: Les isolats de Klebsiella résistants aux carbapénèmes à β-lactamase à spectre étendu (BLSE) sont considérés comme 
l’un des défis les plus importants dans le traitement des patients en milieu hospitalier. Le but de cette étude était de déterminer 
la prévalence d’importants sous-types de BLSE de gènes de résistance au carbapénème et entre K. pneumoniae chez des patients 
hospitalisés à Téhéran, en Iran 
Méthodes: Cinquante-quatre isolats de K. pneumoniae ont été isolés de l'hôpital Shariatee de Téhéran de février 2013 à juillet 
2016. Le test des antibiotiques a été réalisé à l'aide de la méthode de diffusion sur disque standard et du test EIC MIC. La 
confirmation de l'activité de la carbapénémase a été réalisée à l'aide d'un MHT et d'une nouvelle méthode appelée test de la 
méthode d'inactivation du carbapénème (CIM). Enfin, une réaction en chaîne de la polymérase (PCR) et le séquençage de gènes 
apparentés ont été réalisés. 
Résultats: Nos données de PCR démontrent que les 40 gènes du groupe blaCTX-M (81,4%) étaient les plus prévalents dans notre 
hôpital, suivis des gènes du groupe blaCTX-M-3 (18,51%) et blaCTX-M-2 (20,38%). La distribution du groupe CTX-M a révélé 
que blaCTX-M-15 23 (42,6%) était le sous-type dominant. La coexistence de plusieurs gènes comprenait blaTEM, CTX-M 14 et 
blaSHV, et CTX-M). La présence de blaNDM1, de blaOXA-48 et de blaKPC a été identifiée dans les isolats résistants au 
carbapénème, 22 (40,7%), 10 (18,5%) et 7 (12,9%) respectivement. 
Conclusion: nos recherches ont montré qu'un test CIM pour la première fois en Iran est possible et dispose d'une grande facilité 
d'identification rapide de Klebsiella (CRK) résistant au carbapénème. Nous sommes confrontés à l'émergence de souches CTK-
M, OXA-48, KPC et NDM1 hébergeant des souches CRK dans nos hôpitaux. Par conséquent, le traitement des patients infectés 
par ces isolats constituera une préoccupation future importante dans nos environnements cliniques. 
Running Head: Gènes de résistance parmi la pneumonie à Klebsiella résistante au carbapénème 
Mots-clés: métallo-bêta-lactamase-1 de New Delhi, Klebsiella pneumoniae, carbapénème, ß-lactamase à spectre étendu 
 
INTRODUCTION 
In recent years, the use of third-generation 
cephalosporin (TGC) has led to the promotion of a 
selection of β-lactamase producer bacteria that 
performs a hydrolysis of TGC, especially the 
oxyimino-cephalosporins [1,31] .These enzymes, 
capable of hydrolyzing the newer β-lactams, are 
referred to as extended-spectrum β-lactamases 
(ESBLs) [1,2]. At hospital sites, ESBL K. pneumoniae-
resistant isolates are becoming an emerging public 
health concern. The ESBL-producing isolates of 
Klebsiella. spp. (ESBL-K) have been involved in 
several outbreaks of nosocomial infections 
throughout Asia [ 3], including Iran [4,32 ], the United 
States of America [5], the Far East, and Europe [ 6]. 
Recently, blaCTX-M-related genes have appeared as the 
leading type of ESBLs in many parts of the world, 
including Asia, Europe [7], the United States [8], and 
South America [9]. On the basis of amino acid 
sequence, more than 60 variants that include CTX-M-
45, CTX-M-25, CTX-M-9, CTXM-8, CTX-M-2, and 
CTX-M-1 [10]. These Klebsiella ESBL-producing 
isolates may be have. TEM, SHV, and CTX-M-β-
lactamases [10]. ESBL-K strains are prevalent in 
Tehran hospitals, but relatively little data are 
available about β-lactamase genes. Moreover, 
carbapenem antibiotics are useful for treating 
infections caused by ESBL-producing gram-negative 
bacteria. In recent years, carbapenem resistance is 
considered one of the most significant challenges in 
the treatment of patients in hospitals. The rapid 
spread of the carbapenem-hydrolyzing β-lactamase 
KPC between Klebsiella isolates CR in the Tehran 
region has turned alarming. Treatment of infection 
caused by this pathogen has become a matter of 
significant challenge in hospitals in Iran due to its 
high levels of resistance to virtually all classes of 
antibiotics. Therefore, the identification of KPC 
resistance is important for the appropriate choice of 
antibiotic treatment in addition to infection control 
measures to thwart the distribution of resistant 
Klebsiella strains in hospital settings. The aim of this 
study was to determine the prevalence of ESBL 
subtypes and important carbapenem resistance genes 
(KPC/OXA-48/NDM1) among Klebsiella cultured 
from patients at a hospital in Tehran, Iran.  
 
MATERIALS AND METHODS 
Bacterial strains 
The present work is a descriptive cross-sectional 
study carried out from August 2013 to July 2016. 
Fifty-four high-level resistant isolates of K. pneumoniae 
were obtained from Shariatee Hospital in Tehran 






pneumoniae 7881 strain containing the blaSHV and 
blaTEM genes was used as a control. The samples 
yielding the isolates were obtained from different 
wards, including the ICU and ICU General, 
Neurology, Internal ICU, Post HSCT, Post-
hematopoietic Stem Cell Transplantation, BAL 
(Bonchoalveolar lavage), Blood, Hematology, 
Oncology, Emergency, and Gland wards. Antibiotic 
susceptibility was checked as recommended by the 
Clinical and Laboratory Standards Institute (CLSI) 
procedure [11]: Ceftriaxone (CRO: 30 µg), 
Ceftazidime (CAZ: 30 µg), Cefotaxime (CTX: 30 µg), 
Imipenem (IMP: 10µg), Meropenem, Ampicillin-
sulbactam, (ZOX: 30 µg), Gentamicin (GM: 10 µg), 
Amikacin (AN: 30 µg), Ciprofloxacin (CIP: 5 µg) 
(BBL), and K. pneumoniae ATCC 700603 were 
applied as the control in all tests. The Minimum 
Inhibitory Concentrations (MICs) of Imipenem (IMP: 
10 µg) (MAST, Merseyside, UK) against isolates 
showing reduced susceptibility to this carbapenem 
was determined using the E-test MIC assay. 
Antibiotic susceptibility testing was performed as 
recommended by the Clinical Laboratory Standards 
Institute (CLSI) guideline and, using disks, 
Escherichia coli 25922 was applied as a control. The 
MICs for Cp, IMP, MP CAZ, and CRO were 
determined by the E-test method according to CLSI 
guidelines. Isolates exhibiting MIC ≥4 µg were 
screened for the production of ESBL.  
Modified Hodge Testing (MHT) 
The confirmation of carbapenemase activity was done 
using an MHT as previously stated [11]. The K. 
pneumonia, a positive control MHT Positive 
Klebsiella pneumoniae ATCC1705, and MHT 
Negative Klebsiella pneumoniae ATCC1706 were 
used as a positive control. In plates, the presence of a 
distorted or clover leaf-shaped inhibition zone was 
considered as positive for carbapenemase-producing 
isolates, as recommended by the document M100-S24 
of the Clinical and Laboratory Standards Institute 
methods [11,12]. 
Carbapenem Inactivation Method Test (CIM) 
The CIM was performed as previously stated with 
brief changes [3]. The isolates were cultured on MHA 
(Mueller-Hinton agar) plates and a full 12-µl 
inoculation loop of each strain was immersed in 420 
µl of sterile distilled water, and an active 
susceptibility meropenem disc (MEM) was 
homogenized in the solution. After two hours 
incubation at 35°C, the disk was detached and placed 
on an MHA plate inoculated with a suspension of 
OD595 1.25 (correlates with a McFarland value of 0.5) 
standard of susceptible E. coli indicator strain ATCC 
25922 with a sterile cotton swab. Finally, incubation of 
the plate was done at 35°C for 24 h. The results of the 
test were surveyed after overnight incubation: The 
inhibition zone in plates around each disk was 
measured. Plates with inhibition circles <10 mm in 
diameter were considered to indicate CIM positivity 
[13-15]. 
Polymerase chain reaction amplification (PCR) and 
DNA sequence analysis  
The total genomic DNA from the clinical isolates was 
extracted by the boiling method: four colonies of each 
isolate in 600 ml of distilled water for 12 min. and 
centrifuged at 11,000 rpm for 12 min. The supernatant 
was used for the PCR test. PCR amplification was 
performed using the specific primers for the blaKPC 
family, Uni-KPC-F (5’-
ATGTCACTGTATCGCCGTCT-3’) and Uni-KPC-R 
(5’-TTACTGCCCGTTGACGCCC-3’) genes as 
previously described(16). PCR amplification and 
primers for the detection of blaCTX-M, blaTEM, 
blaSHV, blaKPC, blaOXA-48-like, blaNDM, blaVIM, 
and blaIMP genes was carried out as previously 
described by Hosseinzadeh et al. and Fursova et al 
[17,18,33,34]. The sequences were aligned and 
compared using the online BLAST software, (BLAST 
http: //www.ncbi.nlm. nih.gov).  
RESULTS 
Of the eight available antibiotics, the most effective 
was colisitin (100% of the strains were susceptible). 
The results of the antimicrobial susceptibility test are 
shown in Table 1. Distribution of collected samples 
included BAL 22 (40.7%), Wound 5 (9.2%), Urine 9 
(16.6%), Blood 9 (16.6%), Plural 3 (5.5%), Sputum 4 
(7.4%), Abscess 1 (1.8%), and Abdominal 1 (1.8%) 
(Fig.4). Klebsiella spp. was detected in 25.9% (n=14) 
isolates in the <50 years age group and 70.0% (40) 
isolates in the ≥ 50 years age group, but this difference 
was not statistically significant (P > 0.05). Thirty-one 
(57.4%) males and 23 (42.5%) females were infected 
with Klebsiella (Fig.3). Isolates with positive results of 
the carbapenem inactivation method test (CIM) and 
modified Hodge testing (MHT) were considered 
carbapenem-resistant.  MIC results for five antibiotics 
Cp, IMP, MP, CAZ, and CRO showed a high level of 
resistance (MIC≥4). The phenotypic confirmatory test 
showed that among the 54 isolates, 54 (100%) were 
ESBL producers (14). The PCR test of the ESBL-
producing isolates showed that TEM 24 (44.4%) 
isolates were positive for the blaTEM gene, 40 (80.1%) 
positive for the blaCTX-M groups, and 30 (55.6%) 
isolates had the blaSHV gene. Moreover, the SHV types 
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Abbreviations: POST HSCT; Post-hematopoietic stem cell transplantation, BAL; Broncho alveolar lavage, MIC = Minimum 
inhibitory concentration; IMP = Imipenem; MHT = Modified hodge test; DDST = Double disk synergy test; ICU = Intensive 
care unit; Cp= Ciprofloxacin;IMP= Imipenem; MP= Meropenem; CAZ=    Ceftazidime; CRO=Ceftriaxone ; CIM= Carbapenem 
Inactivation method; N= Isolates number; F=Female;M=Male; Cp Genes= Carbapenem Genes; 
Coexistence of multiple gene-encoding ESBLs 
identified among the isolates included blaTEM, CTX-M 
blaSHV, and blaTEM, SHV (Fig. 1). Our PCR data 
demonstrated that among the K. pneumoniae clinical 
strains, blaCTX-M15 23 (42.6%) gene were the most 
prevalent in our hospital followed by group genes 
blaCTX-M2 11 (20.38%) and blaCTX-M3 10 (18.51). The 
distribution of CTX-M groups revealed that blaCTX-M-15 
was the dominant subtype. In the present study, all 44 
CTX-M–harboring Klebsiella isolates studied were 
found to be resistant to cefotaxime and ceftazidime by 
using the standard disk diffusion method and E-test 
MIC, according to the CLSI guidelines. Of the 55 high 
level resistance Klebsiella included in the study, 40 
(74.0%) were found, by the PCR reaction test, to carry 
a carbapenemase-encoding gene, and all PCR-
positives (100%) were shown to produce 
carbapenemase by the CIM except one isolate (Table 
2). The results of MHT in all ESBL isolates were 
positive. BlaNDM1, blaOXA-48 and blaKPC were 
identified in carbapenem-resistant isolates, 22 (%40.7), 
10 (%18.5), and 7 (%12.9) respectively. 
Fig1: Distribution of important Carbapenems resistance 
genes (KPC, OXA-48, and NDM1) among Klebsilla 
cultured from patients 
            
Fig2: The MHT performed on a Muller Hinton Agar 
plate. (1) MH positive result 
 






































Fig4: Distribution of Klebsiella positive samples 
 
DISCUSSION 
ESBL carbapenem-resistant Klebsiella (CRK) strains 
have become globally disseminated in recent years, 
causing concern over the control of hospital infections 
[14]. In this situation, with increasing high-level 
resistant isolates, early detection of CPK strains is 
critical. A study by van der Zwaluw et al. [15] showed 
that CIM is a new method having high specificity and 
sensitivity for detecting carbapenemase producers. 
The modified Hodge test and CIM methods were 
used in our research. Results demonstrated that, of 
the 54 isolates, only one was CIM-negative (2.0%), 
while all the other isolates emerged positive in the 
modified Hodge test. The application of the CIM test 
for the detection of carbapenem-resistant isolates in 
our study showed it is capable of detecting 
carbapenemase production. Using PCR, 40 (74%) of 
these isolates were found to contain a carbapenemase-
encoding gene. These results of CIM are consistent 
with other findings stated by some other researches 
[14,15-19]. With respect to our research, CIM for the 
first time in Iran was found to be very efficient and 
low-cost in the recognition of carbapenemase-
producing K. pneumoniae isolates. In the clinical 
setting, the distribution of ESBL-producing K. 
pneumoniae was considered an important therapeutic 
and epidemiological concern. During the past decade, 
CTX-M.15, CTX-M-14, and CTX-M-2 have been the 
most prevalent CTX-M enzyme in different European 
countries and Iran [20,21]. The present study further 
showed that the CTX-M1 group had a high (92.7%) 
prevalence in clinical ESBL-producing isolates, and 
the most common subtype was CTX-M15. In a study 
by Agamy et al. in Saudi Arabia, a high number of 
isolates (97.3%) carried the blaSHV gene [22]. 
Moreover, Ghafourian et al. [23], in contrast to our 
results in Iran, reported that 94% of K. pneumoniae 
strains harbored the blaSHV genotypes. In our study, 
TEM-1 and SHV-1 subtypes were the majority of 
subtypes of TEM and SHV in K. spp. strains. Further, 
it characterized all the K. pneumoniae isolates from 
the Labbafi Nejad and Zahedan hospitals that carried 
the SHV-11, TEM-1 subtypes, SHV-5, and SHV-12 
were reported to be the dominant ESBLs in Iran 
[24,25]. In agreement with our study, Dedeic-Ljubovic 
et al. confirmed the presence of CTX-M-15 in KPC 
isolates, which belongs to the CTX-M-1 group [20], in 
one of the most important hospitals in Bosnia-
Herzegovina. Researchers in South America 
introduced CTX-M-2 and CTX-M-8 enzymes as the 
predominant ESBL types [26]. Similar to our finding, 
in United States, CTX-M-15 was most common 
genotype but the CTX-M-4 and CTX-M-2 groups were 
rarely detected [26]. In contrast, with a low frequency 
of the CTX-M genotype among KP in the United 
States, our region showed a wide range of strains 
(high prevalence of carbapenem-resistant strains 
harbored blaCTX-M). Of 55 K. pneumoniae isolates, 22 
(40.7) were blaNDM-1 positive. Our findings and 
previous studies indicate that the frequency of 
blaNDM-1 harboring K. pneumoniae strains in Iranian 
hospitals show an increasing trend. A research by 
Zowawi et al. showed that the most common 
carbapenemase were 16 isolates of NDM and 35 
isolates of OXA-48 types [27]. In our finding, the 
blaOXA-48-like gene was identified in 10 (18.5) 


























CIM. Phenotype OXA-48-positive in KPC strains has 
been stated in several regions, including France, 
Russia, Turkey, Saudi Arabia, Taiwan, and China, 
and can be a serious concern in hospital settings [17]. 
In our study, a small number of carbapenem-resistant 
isolates lacked the targeted genes. The reasons for this 
may be the reduced permeability of the outer 
membrane, presence of other genes, AmpC 
betalactamases, and an extended-spectrum beta-
lactamases (ESBLs) [17,28,29]. In the present study, 
we detected the blaKPC gene in just seven (12.9) CR 
isolates that were susceptible to tigecycline and 
polymyxin B. Similar to our findings, other KPC-
harboring isolates revealed a resistance to the 
majority of antimicrobial agents [30]. In summary, we 
have described for the first time the high coexistence 
of blaKPC/NDM1/OXA-48 and blaCTX-M -producing 
Klebsiella. spp. in KP isolates in Tehran, and 
characterized the CIM method as being efficient for 
the detection of CRK strains in hospital settings in 
Iran. 
Conclusion: Our research confirmed that the CIM test 
is practicable in our laboratory and has a high 
capability of fast detection of CRK. We are faced with 
the emergence of CTX-M, OXA-48, KPC, and NDM1 
harboring CRK strains in our hospitals. All isolates 
showed a high level of resistance (ESBL-
positive/carbapenem-positive), indicating a situation 
that was considered to pose a future threat and 
highlighting the necessity of further surveillance in a 
hospital setting. So, with the rapid emergence of 
multi-drug resistance isolates over time, the 
prevention of the spread of the CPK and the initiation 
of appropriate antimicrobial therapy will be a matter 
of serious concern in our clinical settings. 
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